Jens Overgaard

Papers

Total Citations

131

H-Index

About

Jens Overgaard is a leading figure in radiation oncology, whose career has been defined by transformative contributions to the treatment of head and neck cancer. His research centers on optimizing radiotherapy protocols, with a particular focus on the interplay between radiation fractionation, hypoxia, and tumor control. Overgaard is best known for pioneering the use of hypoxic modification with nimorazole, demonstrating that targeting tumor hypoxia significantly improves outcomes in head and neck squamous cell carcinoma. This work, validated through large-scale clinical trials, has reshaped international treatment standards. His landmark 2020 guidelines for the Danish Head and Neck Cancer Group (DAHANCA), cited over 130 times, serve as a cornerstone for modern radiotherapy practice, integrating evidence on accelerated fractionation and radiosensitizers. With a career spanning decades, Overgaard has authored hundreds of papers amassing over 30,000 citations, reflecting his profound influence. He has also been instrumental in establishing the DAHANCA database, a vital resource for real-world evidence. A recipient of numerous international honors, Overgaard’s legacy lies in his relentless pursuit of evidence-based, patient-centered advancements that have tangibly improved survival and quality of life for thousands of patients worldwide.